Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
about
Anti-nerve growth factor in pain management: current evidenceA Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat.Towards a mechanism-based approach to pain management in osteoarthritisManagement of Osteoarthritis with Avocado/Soybean Unsaponifiables.A fully caninised anti-NGF monoclonal antibody for pain relief in dogsMonoclonal antibodies for the treatment of osteoarthritis.Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.Neurotrophins in bladder function: what do we know and where do we go from here?Pro-neurotrophins, sortilin, and nociception.Central pain processing in osteoarthritis: implications for treatment.Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.Emerging drugs for the treatment of knee osteoarthritis.Mechanisms and Mediators That Drive Arthritis Pain.Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain.Skeletal complications in cancer patients with bone metastases.Tanezumab in the treatment of chronic musculoskeletal conditions.Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.[EXPRESS] Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.From Mechanism to Cure: Renewing the Goal to Eliminate the Disease of Pain.One-year outcome of postoperative swallowing impairment in pediatric patients with posterior fossa brain tumor.Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension.Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.A novel rat model of hip pain by intra-articular injection of nerve growth factor-characteristics of sensory innervation and inflammatory arthritis.Japanese GWAS identifies variants for bust-size, dysmenorrhea, and menstrual fever that are eQTLs for relevant protein-coding or long non-coding RNAs.First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.Mechanisms of Osteoarthritis (OA) Pain
P2860
Q26746194-44A4ED1A-5439-45BE-8A48-A85885CBC181Q33819340-BFB7AFA6-E813-401D-9194-431F4625A471Q34120813-E42D5482-F088-4506-9D9E-B1B1325E3CCDQ34459643-C65E06B6-FE23-4CD0-AD62-717F3FBE58B4Q35037390-B2AFFB10-0174-4A8A-A2D4-0ECD325E8F6CQ36113839-60A2BB09-CC52-4389-9F0C-F87212CEACB1Q36236043-A03C3F7E-568C-4858-9289-C09BE91DAD8EQ36706795-658D879F-4A05-49F3-9F41-A05F1A7DCA37Q37604491-3C473B40-9645-4EF7-9C79-91F85F237F8DQ38115263-0F8AD280-A408-40F0-B568-93A4A4B44DAEQ38185068-666EB9FA-C6F4-4E89-BD28-84A16C27B475Q38196918-F04C00BE-98AB-4E61-B68D-6980A6EC1EB7Q38210286-50604CBC-506C-4FFB-A5AB-20D1C131EB11Q38417521-54C2F93A-AA81-48C6-B573-DC749EBDA5EAQ38508116-9056AA12-D4F0-4F99-B8D3-F10B80566A1FQ38646694-A0245FE6-B563-45C9-891A-81460DB271E2Q38917438-2AE99649-C560-4D52-80E7-81B21A3C76E8Q39034462-00CA6094-C964-4F5A-BA71-F26EC323D2A9Q39195605-BC1D2DFB-9C89-44DC-8480-E4C9706AD46EQ39209120-40F23A3B-C887-4055-AC29-348CB404B731Q39210251-18F7462B-BF1D-428F-AFF2-3D5BBECAF17FQ43525106-9555933D-9EBE-44BA-B393-8EC81F729F35Q46156381-F9AAA3D1-EA06-4553-BD73-B953DF0317F2Q47566382-6AD8FEEF-3060-4232-99E7-2E912C9D4296Q47896405-16035197-7072-473B-B7EA-F8CDD6F843F3Q49402122-D570C3D3-D8CF-47C4-84D9-06A094EA4E0AQ50969268-A0DD47C6-DDE2-4924-AE9C-AAD091515CFFQ52593024-D8BCF095-14D6-452C-A8EB-49786462B600Q53590330-775E4095-D2C6-418D-837D-26EE3EBA9F1EQ55054458-28890E92-BA9A-4E84-8EC2-BF2453E5BF7EQ55264146-4B7BE1A3-A87B-48CA-887A-2C24EB4679E5Q58697448-B4E0F0CD-DBF6-432F-BAEE-573BE8897649
P2860
Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@ast
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
type
label
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@ast
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
prefLabel
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@ast
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@nl
P2093
P2860
P921
P356
P1476
Tanezumab reduces osteoarthrit ...... bo-controlled phase III trial.
@en
P2093
Christine R West
David M Radin
Frederick T Murphy
Isabelle Davignon
Mark T Brown
Michael D Smith
P2860
P304
P356
10.1002/ART.37950
P577
2013-07-01T00:00:00Z